Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 9Other hematologic neoplasm 7Myeloid 4Plasma cell 2Sarcoma 1Head & Neck 1Genitourinary 1Endocrine 1CNS 1

Conditions

Sarcoma 7Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Salivary Gland Neoplasms 3Head and Neck Neoplasms 3Gastrointestinal Stromal Tumors 3Central Nervous System Neoplasms 3Breast Neoplasms 3Brain Neoplasms 3Thyroid Diseases 2Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neuroblastoma 2Neoplasms by Site 2Melanoma 2Medulloblastoma 2Lung Neoplasms 2Lung Diseases 2Glioma 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2

Interventions

entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Recurrence × Sarcoma × Clear all
NCT02650401 2026-03-25

STARTRK-NG

Hoffmann-La Roche

Phase 1/2 Active not recruiting
69 enrolled 1 FDA
CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡